Vitrafy Life Sciences Limited (ASX:VFY)
Australia · Delayed Price · Currency is AUD | Market Cap | 162.82M +73.5% |
| Revenue (ttm) | 2.34M +51.9% |
| Net Income | -14.15M |
| EPS | -0.22 |
| Shares Out | 63.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 71,205 |
| Average Volume | 65,047 |
| Open | 2.500 |
| Previous Close | 2.500 |
| Day's Range | 2.500 - 2.650 |
| 52-Week Range | 1.160 - 2.750 |
| Beta | n/a |
| RSI | 71.49 |
| Earnings Date | Apr 28, 2026 |
About Vitrafy Life Sciences
Vitrafy Life Sciences Limited engages in the research, development, and commercialization of cryopreservation solutions in Australia. The company offers smart devices, such as smart cryopreservation, smart thawing, and smart packaging devices. It also provides a software platform, which controls, trace, tracks, and monitors quality of cryopreserved biomaterials under the LifeChain brand. The company’s cryopreservation technology is used various applications, such as blood platelets, cell and gene therapies, and aquaculture and bovine breeding p... [Read more]
Financial Performance
In fiscal year 2025, Vitrafy Life Sciences's revenue was 1.05 million, a decrease of -49.14% compared to the previous year's 2.06 million. Losses were -32.71 million, 213.8% more than in 2024.
Financial StatementsNews
Vitrafy Life Sciences Earnings Call Transcript: Q3 2026
Strong progress in blood, cell and gene therapy, and animal reproduction verticals, with phase II U.S. military blood platelets testing completed and positive results driving commercial interest. Cash position remains robust at AUD 18.5 million, supporting expansion and regulatory milestones.
Vitrafy Life Sciences Transcript: NWR Virtual Healthcare Conference
Cryopreservation underpins critical healthcare sectors but relies on outdated technology, prompting the development of a smart, connected ecosystem targeting animal reproduction, blood products, and cell/gene therapy. Strategic partnerships, U.S. expansion, and FDA approval are set to drive growth.
Vitrafy Life Sciences Earnings Call Transcript: H1 2026
Secured first commercial contract in animal reproduction, progressed U.S. human health market entry, and maintained a strong cash position. Near-term catalysts include Phase II U.S. Army study results, FDA registration, and ramped device manufacturing to meet growing demand.
Vitrafy Life Sciences Earnings Call Transcript: Q2 2026
Secured a major commercial agreement with IMV, expanded U.S. operations, and maintained a strong cash position nearing AUD 23 million. Focus remains on executing commercial deals, expanding manufacturing, and targeting high gross margins through cost reductions.
Vitrafy Life Sciences Transcript: Bell Potter Healthcare Conference 2025
Breakthrough cryopreservation technology is set to transform animal and human health markets, with strong U.S. Army trial results, robust IP, and a managed service model driving rapid scaling. Commercial focus is on blood platelets and cell/gene therapy, with North American expansion underway.
Vitrafy Life Sciences Transcript: AGM 2025
Leadership transition and strategic focus on North American expansion, commercialization, and operational scaling were highlighted. Financial discipline remains a priority, with strong cash reserves and grant support. All AGM resolutions passed, and a live demonstration of the Guardian device marked a key milestone.
Vitrafy Life Sciences Earnings Call Transcript: Q1 2026
Major milestones achieved with the VCU2 device and LifeChain software, supporting immediate market entry and strong commercial pipeline. Cash position remains robust, with a runway into 2027 and key regulatory and commercialization milestones targeted for 2026.
Vitrafy Life Sciences Earnings Call Transcript: H2 2025
Leadership transition and strong execution on IPO commitments, including successful ASX listing, capital raise, and grant funding, position the company for accelerated commercialization. Revenue growth, robust cash reserves, and product launches in key markets underpin a positive outlook.
Vitrafy Life Sciences Earnings Call Transcript: Q3 2025
Vitrafy achieved strong operational and financial progress, highlighted by a successful US Army platelet study, a major government grant, and rapid growth in aquaculture. Product development and US commercialization are accelerating, with a robust cash position supporting expansion.